Invitrocue
PrivateLast Round
Convertible Debt
Dec 6, 2019
Total Funding Raised
$750,000
Company Overview
Invitrocue operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was a Convertible Debt round in October 2019.
Invitrocue is a biotechnology research company that provides bio-analytic solutions, including in-vitro cell-based testing technologies, 3D cell-based models, and image analytics for drug development and personalized oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Invitrocue Comparables
Compare Invitrocue with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Xilis | 85% | |
| Kiyatec | 84% | |
| Tempus | 71% |
For institutional investors. Book with your work email.
Invitrocue Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Dec 6, 2019 | ||||
| Convertible Debt | Oct 1, 2019 | ||||
| Reverse Merger | Jan 27, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Invitrocue Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ChinaLink ESGt | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 20, 2026
Monthly visitors increased 93% MoM.
- Nov 8, 2025
Monthly visitors grew 307% MoM, reaching 2.9K.
For institutional investors. Book with your work email.
Invitrocue Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Invitrocue's valuation, stock price, and market status.
Is Invitrocue a public or private company?
Invitrocue is a private company.
What is the current stock price of Invitrocue?
Invitrocue is a private company, so its shares have no public market price. Caplight tracks Invitrocue's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Invitrocue worth (valuation)?
Valuation information for Invitrocue is not publicly available.
Can I buy Invitrocue stock?
Invitrocue shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Invitrocue's last funding round?
Invitrocue's most recent funding round was Convertible Debt on December 6, 2019.
Who are the main investors in Invitrocue?
Key investors in Invitrocue include ChinaLink ESGt.
Will Invitrocue IPO soon?
No public IPO plans have been announced for Invitrocue.
How can I track Invitrocue secondary market activity?
Caplight tracks bids, offers, and trades in Invitrocue's shares on secondary markets.